Chronic Lymphocytic Leukemia. - Cancer Stat Facts [Internet]. SEER. https://seer.cancer.gov/statfacts/html/clyl.html

Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6. https://doi.org/10.1056/NEJM200012283432602.

Article  PubMed  Google Scholar 

Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013;5:47. https://doi.org/10.1186/gm451.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440–50. https://doi.org/10.1182/bloodadvances.2021006434.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739–54. https://doi.org/10.1056/NEJMoa2213093.

Article  CAS  PubMed  Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–36. https://doi.org/10.1056/NEJMoa1815281.

Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus Chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14:2147. https://doi.org/10.1038/s41467-023-37648-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ Nat Publishing Group. 2018;25:46–55. https://doi.org/10.1038/cdd.2017.179.

Article  CAS  Google Scholar 

Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–96. https://doi.org/10.1182/blood-2011-01-328484.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, et al. Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123:1207–13. https://doi.org/10.1182/blood-2013-07-515361.

Article  CAS  PubMed  Google Scholar 

Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8:2300–9. https://doi.org/10.1182/bloodadvances.2023012221.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892–901. https://doi.org/10.1016/S0140-6736(21)00224-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918–27. https://doi.org/10.1158/1078-0432.CCR-19-2856.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woyach JA, Blachly JS, Rogers KA, Bhat SA, Jianfar M, Lozanski G, et al. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discov. 2020;10:394–405. https://doi.org/10.1158/2159-8290.CD-19-1130.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388:319–32. https://doi.org/10.1056/NEJMoa2211582.

Article  CAS  PubMed  Google Scholar 

Gordon BK, Woyach JA. The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics. Leuk Lymphoma. 2025;66:838–46. https://doi.org/10.1080/10428194.2024.2445688.

Article  CAS  PubMed  Google Scholar 

Easaw S, Ezzati S, Coombs CC. SOHO state of the art updates and next questions: updates on BTK inhibitors for the treatment of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2023;23:697–704. https://doi.org/10.1016/j.clml.2023.07.011.

Article  CAS  PubMed  Google Scholar 

Stanchina MD, Montoya S, Danilov AV, Castillo JJ, Alencar AJ, Chavez JC, et al. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024;21:867–87. https://doi.org/10.1038/s41571-024-00956-1.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441–52. https://doi.org/10.1200/JCO.21.01210.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CS, Opat S, D’Sa S, Jurczak W, Lee H-P, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038–50. https://doi.org/10.1182/blood.2020006844.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CSL, Garcia-Sanz R, Opat S, D’Sa S, Jurczak W, Lee H-P, et al. ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM). J Clin Oncol Wolters Kluwer. 2022;40:7521–7521. https://doi.org/10.1200/JCO.2022.40.16_suppl.7521.

Article  Google Scholar 

Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94. https://doi.org/10.1056/NEJMoa1400029.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skarbnik AP, Danilov AV, Hoffmann M, Awan FT, Scarpa F, Davies C, et al. Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis). Blood. 2024;144:4623. https://doi.org/10.1182/blood-2024-209590.

Article  Google Scholar 

Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med. 2022;386:735–43. https://doi.org/10.1056/NEJMoa2114110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molica S, Allsup D, Giannarelli D. Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta-Analysis. Am J Hematol. 2025;100:334–7. https://doi.org/10.1002/ajh.27544.

Article  CAS  PubMed  Google Scholar 

Blombery P, Chatzikonstantinou T, Gerousi M, Rosenquist R, Gaidano G, Pospisilova S, et al. Resistance to targeted therapies in chronic lymphocytic leukemia: current status and perspectives for clinical and diagnostic practice. Leuk Nat Publishing Group. 2025;1–12. https://doi.org/10.1038/s41375-025-02662-y.

Woyach JA, Jones D, Jurczak W, Robak T, Illés Á, Kater AP, et al. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024;144:1061–8. https://doi.org/10.1182/blood.2023023659.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non–Hodgkin lymphoma. Cancer Discov. 2024;14:66–75. https://doi.org/10.1158/2159-8290.CD-23-0670.

Article  CAS  PubMed  Google Scholar